Senior management changes at Biodel
This article was originally published in Scrip
The US speciality pharmaceutical company Biodel has named Dr Errol De Souza president and chief executive officer and Dr Charles Sanders board chairman. Dr Solomon Steiner, who co-founded Biodel in 2003, will become chief scientific officer and will remain a member of the board. Dr Sanders is the former chairman and CEO of Glaxo and was appointed to Biodel’s board in 2006. Dr De Souza has previously served as president and CEO of Synaptic Pharmaceuticals, president and CEO of Archemix, co-founder and chief scientific officer of Neurocrine Biosciences, senior vice-president and US site head of drug innovation and approval at Aventis and director of CNS diseases research at DuPont Merck. With the appointment of a non-executive board chairman, Biodel has eliminated the role of lead director, which had been held by director Scott Weisman.
You may also be interested in...
US-based law firm Morgan Lewis has appointed Donna Lee Yesner and Stephen Ruscus as partners in its Food and Drug Administration and healthcare practice, based in Washington, DC. Ms Yesner is the co-chair of the healthcare contracting committee of the ABA Public Contracts Section, while Mr Ruscus focuses his practice on public healthcare, government contracts and litigation.
Qforma, a provider of analytics and predictive modelling technologies for the health sciences industry, has elected Mark Spiers to its board of directors. Mr Spiers retired as president and CEO of Wolters Kluwer Pharma Solutions in April; he has also previously worked for Bristol-Myers Squibb, Pharmacia and MedPointe Pharmaceuticals.
The San Diego, California-based biopharmaceutical company Optimer Pharmaceuticals has appointed Dr Nancy Ruiz senior vice-president of R&D, Cynthia Schwalm senior vice-president of international and Dr Kasia Petchel senior vice-president of pharmacovigilance. These newly created positions will strengthen the company's management team as it prepares for the potential launch of its lead product candidate, Dificid (fidaxomicin). Dr Ruiz joins from Merck Research Laboratories (formerly Schering-Plough Research Institute), where she served as vice-president of project and pipeline management for infectious diseases. Ms. Schwalm was previously president of Eisai Pharmaceuticals, the US commercial arm of Tokyo-based Eisai Co, while Dr Petchel was formerly vice-president of global head drug safety risk management at Roche.